CDEK
← All organizations

Solstice Neurosciences

For profitContributed to NME

Also known as: Solstice Neurosciences | Solstice NeuroSciences, LLC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jan 1, 2003

Last known activity

Nov 30, 2021

Acquired by US WorldMeds on Jan 1, 2010

Timeline

2000s

  1. Dec 8, 2000

    rimabotulinumtoxinB— NDA Organization

  2. Dec 8, 2000

    rimabotulinumtoxinB— NDA Secondary Org

  3. Jan 1, 2003

    Solstice Neurosciences— Founded

2010s

  1. Jan 1, 2010

    US WorldMeds— Acquired By

Drugs by trial phase (1 distinct, 5 trials)

Phase 4 (1 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

Recent trials (6)

Details

Founded
Malvern, PA, US Jan 1, 2003
Last known activity
Nov 30, 2021

Designations held

  • Orphan drug